Drug rediscovery in gastroenterology: from off-label to on-label use of thioguanine in inflammatory bowel disease

被引：2

作者：

de Boer, Nanne K. H. ^{[1
,2
,6
]}

Simsek, Melek ^{[1
,3
]}

Meijer, Berrie ^{[1
,3
]}

Neurath, Markus F. ^{[4
]}

van Bodegraven, Ad ^{[5
]}

Mulder, Chris J. J. ^{[1
]}

机构：

[1] Univ Amsterdam, Gastroenterol & Hepatol, Med Ctr, Amsterdam, Netherlands

[2] Res Inst Amsterdam Gastroenterol Endocrinol Metab, Amsterdam, Noord Holland, Netherlands

[3] Vrije Univ Amsterdam, Sch Med, Amsterdam, Netherlands

[4] Friedrich Alexander Univ Erlangen Nurnberg, Dept Med 1, Erlangen, Germany

[5] Zuyderland Med Ctr, Dept Gastroenterol Geriatr & Intens Care Med Co M, Geleen, Netherlands

[6] Univ Amsterdam, Gastroenterol & Hepatol, Med Ctr, NL-1081 HZ Amsterdam, Netherlands

来源：

GUT | 2023年 / 72卷 / 10期

关键词：

drug development; drug metabolism; inflammatory bowel disease; crohn's disease; azathioprine; ULCERATIVE-COLITIS; THIOPURINE THERAPY; AZATHIOPRINE; PHARMACOGENETICS; INHIBITION; 6-THIOGUANINE; PROLIFERATION; ASSOCIATION; COMBINATION; ACTIVATION;

D O I：

10.1136/gutjnl-2023-329679

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Drug rediscovery refers to the principle of using 'old' drugs outside the indications mentioned in the summary of product characteristics. In the past decades, several drugs were rediscovered in a wide variety of medical fields. One of the most recent examples is the unconditional registration of thioguanine (TG), a thiopurine derivative, in patients with inflammatory bowel disease in the Netherlands. In this paper, we aim to visualise potential hurdles that hamper drug rediscovery in general, emphasise the global need for optimal use and development of potentially useful drugs, and provide an overview of the registration process for TG in the Netherlands. With this summary, we aim to guide drug rediscovery trajectories in the near future.

引用

页码：1985 / 1991

页数：7

共 50 条

[1] On-label and off-label drug use in the treatment of endometriosis
Quaas, Alexander M.
Weedin, Elizabeth A.
Hansen, Karl R.
[J]. FERTILITY AND STERILITY, 2015, 103 (03) : 612 - 625
[2] Off-label drug use in inflammatory bowel disease in The Netherlands
Mulder, Chris J.
[J]. SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2018, 108 (08): : 691 - 691
[3] On-label and off-label drug use in the treatment of female infertility
Usadi, Rebecca S.
Merriam, Kathryn S.
[J]. FERTILITY AND STERILITY, 2015, 103 (03) : 583 - 594
[4] Introduction: On-label and off-label drug use in reproductive medicine
Legro, Richard S.
[J]. FERTILITY AND STERILITY, 2015, 103 (03) : 581 - 582
[5] Converting a drug from off-label to on-label use: Government subsidies and patient welfare
Olsder, Wendy
Martagan, Tugce
Tang, Christopher S.
[J]. DECISION SCIENCES, 2023, 54 (06) : 579 - 595
[6] Statins for inflammatory bowel disease: Can off-label drug help it?
Bifulco, Maurizio
Ciaglia, Elena
[J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2017, 38 : E23 - E23
[7] Classification and characteristics of on-label and off-label apixaban use in Denmark and Sweden
Vinter, Nicklas
Linder, Marie
Andersen, Morten
Pedersen, Alma B.
Madsen, Morten
Schachterle, Stephen E.
Ataher, Quazi
Mo, Jingping
Johnsen, Soren Paaske
Ehrenstein, Vera
[J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (06) : 867 - 878
[8] Trends in On-label and Off-label Modafinil Use in a Nationally Representative Sample
Penaloza, Renee A.
Sarkar, Urmimala
Claman, David M.
Omachi, Theodore A.
[J]. JAMA INTERNAL MEDICINE, 2013, 173 (08) : 704 - 706
[9] Prevalence of use of on-label and off-label psychotropics in the Greek pediatric population
Pesiou, Stella
Barcelo, Rafel
Papazisis, Georgios
Torres, Ferran
Pontes, Caridad
[J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
[10] Severe thrombocytopenia in a patient with hepatitis C treated with eltrombopag from off-label drug use to on-label drug use: A case report
Al-Jafar H.A.
Al-Khaldi J.
Alduaij A.
Al-Banwan K.
[J]. Journal of Medical Case Reports, 8 (1)

← 1 2 3 4 5 →